Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Countries
- 3
01
Overview
Phase 1, randomised trial of LY4405094 in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Serious Adverse Events at 25 weeks. Started Oct 2025; status: recruiting.
02
Drugs
LY4405094
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07787182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787182.